Healthcare, Pharmaceuticals and Biotech
Kroll Life Sciences Webcast Series
Pharmaceutical, healthcare, biotech and medical device companies face a challenging, competitive health landscape. Pricing pressures, scientific breakthroughs, expanding demand for healthcare access and emerging digital and analytic capabilities push companies to explore unconventional business models and build value-based customer relationships. Kroll recently brought together our leading experts and industry leaders to share insights and trends on valuation, technology, intellectual property (IP), risk and regulation in a life sciences webcast series.
Kroll helps organizations in the healthcare, pharmaceuticals and biotechnology sectors address complex business challenges related to governance, risk and transparency.
Pharmaceutical, healthcare, biotech and medical device companies face a challenging, competitive health landscape. Pricing pressures, scientific breakthroughs, expanding demand for healthcare access and emerging digital and analytic capabilities push companies to explore unconventional business models and build value-based customer relationships.
Underpinning these dynamics is the uncertainty created by a post-COVID-19 environment. The implications have been far-reaching and will likely impact the entire life science ecosystem. While companies need to be aware of the risks to their organization, Kroll understands the complexity of these challenges and works with clients worldwide to drive progress, navigate new opportunities and manage risk.
Our life sciences specialists bring practical, in-depth experience to healthcare and life sciences companies, including consumer health, medical devices, diagnostics and pharmaceuticals. We help our clients address their most pressing challenges in in the areas of valuation, expert services, investigations, cyber risk, corporate finance, security, restructuring, legal and business solutions, data analytics, due diligence and regulatory compliance.
Please join us June 21-24 for Kroll’s Life Sciences week. We will bring together our leading experts and industry leaders to set the roadmap for a new era where pharma, patients, providers and society are united in their efforts of greater value.
We will provide insights for pharmaceutical and life sciences professionals on operational risk, compliance, supply chain, health and safety and technology, including:
- “Deep-dive interviews” with industry leaders demonstrating examples on their approach
- Inherent risks impacting the industry
- Case studies on how the life science industry has managed to adapt to market changes
- Commentary on the latest regulation, technology developments and industry trends
- Panel discussions that cover the most important challenges due to the impact of COVID-19
Valuation and consulting for financial reporting, federal, state and local tax, investment and risk management purposes.
Healthcare expertise for middle-market M&A transactions.
Transaction Advisory Services
Seamless analytical advisory through the deal continuum, from transaction origination to closing.
Built upon the foundation of its renowned valuation business, Duff & Phelps' Tax Services practice follows a detailed and responsive approach to capturing value for clients.
Forensic Investigations and Intelligence
Providing clients with global investigative expertise to help make critical decisions and mitigate risk.
Global, end-to-end cyber risk solutions.
Security Risk Management
Helping clients anticipate/respond to a myriad of facility, operational and employee security challenges.
Compliance Risk and Diligence
Complying with anti-money laundering and anti-bribery and corruption regulations.
Independent expert analysis, testimony, advice and investigations for complex disputes and projects.
Financial Services Compliance and Regulation
Local and global compliance expertise for the financial services industry.
New Trends Identified – Kroll's 2021 Anti-Bribery and Corruption Benchmarking Report
Kroll Alternative Investments Virtual Conference
Life Sciences Webcast Series
A Panel of Experts Discusses Navigating Price Gouging Rules
Operational Risk Trends in Life Sciences
Protection of Vaccine Supply Chain
Kroll named the “Most Improved Firm” in Exelon’s 2021 Diversity, Equity & Inclusion Honor Roll
Kroll Institute Appoints Megan Greene as Global Chief Economist
Kroll Appoints Shai Waisman as Firm President
World’s Biggest Corporates Hit Hardest by Illicit Activity Despite Bolstering Defenses, Reveals Kroll